Navigation Links
Drug Cuts Muscle Damage After Heart Attack
Date:2/14/2008

Safety trial shows novel compound blocks enzyme triggering cell and tissue death

THURSDAY, Feb. 14 (HealthDay News) -- A drug designed to lessen muscle damage from a heart attack has passed initial safety tests in humans.

The drug, known as KAI-9803, blocks the activity of an enzyme called delta protein kinase C that triggers cell and tissue death in the aftermath of percutaneous coronary intervention (PCI). PCI is a set of procedures including balloon angioplasty and stent placement that clear and prop open clogged coronary blood vessels that lead to a heart attack.

Although the trial was not designed to demonstrate the efficacy of KAI-9803, researchers said early data suggest it appears to be a promising compound. Results of the study, done at the Duke Clinical Research Institute, are available online and are expected to be published in the Feb. 19 issue of Circulation.

Earlier studies in animals showed that KAI-9803 lessened damage to the heart muscle and quickly restored its pumping function.

"We may not be able to intervene in the first stage of a heart attack, but we think there may be ways to limit damage caused by reperfusion injury," lead investigator Dr. Matthew Roe, a cardiologist at Duke, said in a prepared statement.

The heart suffers damage at two major points in a heart attack, Roe said: first, when a blockage in a coronary artery prevents blood and oxygen from getting to the heart, and then again when the patient undergoes PCI and normal blood flow is restored through reperfusion.

Researchers randomized 154 patients who had suffered heart attacks and were eligible for PCI into either one of four dosing levels of KAI-9803 or a placebo. Patients underwent PCI with physicians injecting the drug directly into their coronary blood vessels during the procedure.

"We designed the trial to find out if KAI-9803 is safe for humans, and we accomplished that goal; we did not see any serious side effects," Roe said. "We also found, however, many promising signs of beneficial drug activity such as lessened damage to the heart muscle and improvement in electrical conductivity in the heart that corresponded to restoration of blood flow to the heart muscle. As a result, we feel this drug has the potential to be helpful in reducing the impact of a heart attack in humans."

More information

To learn more about heart attack warning signs and prevention, visit the National Heart, Lung, and Blood Institute.



-- Kevin McKeever



SOURCE: Duke University Medical Center & Health System, news release, February 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Single Mutation in Mitochondrial DNA Weakens Heart, Muscles
2. Muscle Fatigue Drug May Fight Heart Failure
3. StopMusclePain.com Launched as Only Website Dedicated to Reversing Back Pain
4. Oregon researchers find trigger gene for muscle development
5. Drugs to bulk up muscles may make injuries more likely
6. Embryonic Stem Cells Create Healthy Muscle in Mice
7. New insight into factors that drive muscle-building stem cells
8. Strength training of neck muscles relieves chronic pain
9. Stimulating muscles may improve musicians dystonia
10. SLU researchers show how to stop muscle weakness caused by myasthenia gravis
11. MRE could provide a definitive diagnosis for people with muscle pain, Mayo Clinic study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Cuts Muscle Damage After Heart Attack
(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: